| Neuroimmune Axis in AD | |
|---|---|
| Genes | [TREM2](/genes/trem2), [CD33](/genes/cd33), [PLD3](/genes/pld3) |
| Cell Type | Microglia (primary), neurons (PLD3) |
| Pathway | Innate immune regulation, phagocytosis, autophagy-lysosomal function |
| Direction | TREM2 activates, CD33 inhibits, PLD3 clears |
| AD Relevance | All three are established AD risk genes |
Three genetically-validated neuroimmune genes—TREM2, CD33, and PLD3—form a regulatory axis that controls microglial function and the autophagic-lysosomal pathway in Alzheimer's disease. Together, they represent the brain's innate immune response to amyloid and tau pathology, and constitute some of the most promising therapeutic targets for disease modification[1].
These three genes operate at different levels of the same biological system:
The convergence of all three genes on amyloid clearance and lysosomal function—processes central to AD pathogenesis—makes the neuroimmune axis a high-priority target for therapeutic intervention. A comprehensive review by Ulrich et al. (2017) in Neuron titled "A decade of TREM2 in Alzheimer's disease" provides the foundational framework for understanding this axis[4].
The three-gene axis can be conceptualized as a rheostat that controls microglial activation state in response to AD pathology. Wang et al. (2020) demonstrated that TREM2 mediates microglial survival through metabolic adaptation, providing a mechanistic basis for its protective role[5]. Gratuze et al. (2018) showed that reinstating TREM2 expression in TREM2-deficient models rescues amyloid clearance, establishing the causal relationship[6]. Meanwhile, Griciuc et al. (2013) in Neuron demonstrated that CD33-dependent inhibition of microglial Aβ clearance is a major mechanism of AD risk[7], while Mazza et al. (2013) confirmed these findings through mouse model studies[8].
TREM2 is the primary activating receptor in the neuroimmune axis, driving microglial transition to disease-associated microglia (DAM)[9]. Jiang et al. (2023) published a comprehensive review of TREM2 in AD in Molecular Psychiatry covering the full spectrum from basic research to clinical translation[10].
| Variant | Population Frequency | AD Risk (OR) | Mechanism |
|---|---|---|---|
| R47H | ~0.6% European | ~3.0 | Loss of ligand binding |
| R62H | ~1.0% European | ~1.5 | Partial loss of function |
| D87N | Rare | ~2.0 | Reduced signaling |
TREM2 variants confer AD risk comparable to a single APOE4 allele[11].
TREM2 signaling drives:
The structural basis for TREM2 ligand recognition and signaling was elucidated by Olofsson et al. (2022) in Nature Structural and Molecular Biology[15]. TREM2 signals through its adaptor protein DAP12 (TYROBP), which contains an ITAM domain that activates SYK family kinases. Zhao et al. (2023) in Nature Neuroscience showed that TREM2 and TYROBP jointly regulate microglial homeostatic and disease-associated states[16].
TREM2 agonists (e.g., AL002A in Phase 2 trials) aim to restore or enhance TREM2 signaling[17]:
CD33 is the primary inhibitory receptor in the neuroimmune axis, suppressing microglial phagocytosis through ITIM-mediated signaling[18]. Song et al. (2022) reviewed CD33 as a therapeutic target in Trends in Pharmacological Sciences[19].
| Variant | Allele | AD Effect | Mechanism |
|---|---|---|---|
| rs3865444 (C) | Protective | ~15% reduced risk | Splicing variant, reduced CD33M |
| rs12459419 (T) | Risk | ~8% increased risk | Increased full-length CD33 |
The protective allele creates a splice variant that skips exon 2, reducing expression of the full-length inhibitory receptor[20].
CD33 signaling inhibits:
The two receptors constitute a rheostat controlling microglial activation state[21]:
| Signal | Receptor | Adaptor | Effect |
|---|---|---|---|
| Activating | TREM2 | DAP12 (ITAM) | SYK activation, phagocytosis ON |
| Inhibiting | CD33 | SHP-1/2 (ITIM) | SYK deactivation, phagocytosis OFF |
Genetic variants in both genes show additive or multiplicative effects on AD risk, confirming their epistatic relationship[22].
A landmark study by Yang et al. (2024) in Nature Metabolism demonstrated that CD33 modulates microglial metabolism in AD, linking immune signaling to metabolic reprogramming[23]. Liao et al. (2022) confirmed that CD33 modulates metabolic and phagocytic capacity in microglia[24].
CD33 antagonists aim to remove the inhibitory brake on microglial function[25]:
| Strategy | Mechanism | Status |
|---|---|---|
| Anti-CD33 antibodies | Block ITIM signaling | Preclinical |
| ASO splice modulators | Promote protective isoform | Preclinical |
| Small molecule ITIM blockers | Prevent SHP recruitment | Discovery |
Anti-CD33 therapy has shown efficacy in preclinical models, reducing amyloid and tau pathology in mouse models[23:1]. Schwarting et al. (2022) in Nature Neuroscience demonstrated that CD33 genetic variation is associated with tauopathy, extending the therapeutic relevance beyond amyloid[26].
PLD3 is the downstream effector that ensures lysosomal degradation of engulfed material[27]. Vaughan et al. (2018) reviewed PLD3's role in neuronal development and neurodegenerative disease in Trends in Neurosciences[28].
| Variant | Frequency | AD Risk (OR) | Effect |
|---|---|---|---|
| p.Val255Met | ~0.5% | ~2.5 | Impaired lysosomal targeting |
| p.Arg520Cys | ~0.3% | ~2.0 | Reduced protein stability |
| p.Leu308Pro | ~0.2% | ~3.0 | Decreased function |
PLD3 AD risk was discovered through whole-exome sequencing, identifying rare coding variants as the causal mechanism[3:1].
PLD3 regulates:
PLD3 deficiency also contributes to tau pathology through shared lysosomal mechanisms[26:1]:
Schwarting et al. (2023) in Acta Neuropathologica Communications demonstrated that PLD3 variants modulate tau pathology and lysosomal function in neurons[31]. Cottrell et al. (2021) reviewed the connection between PLD3 and the autophagic-lysosomal pathway in neurodegeneration[32].
Gaucher et al. (2020) in EMBO Molecular Medicine showed that PLD3 deficiency leads to lysosomal dysfunction and neurodegeneration[27:1]. Chen et al. (2023) in EMBO Reports demonstrated that PLD3 knockout in mouse models leads to lysosomal dysfunction and neurodegeneration[33].
| Strategy | Approach | Status |
|---|---|---|
| Gene therapy | AAV-PLD3 delivery | Preclinical |
| Small molecule correctors | Stabilize variant proteins | Discovery |
| Chaperone therapy | Improve folding | Early research |
All three genes ultimately converge on lysosomal function—the terminal compartment for degrading protein aggregates. Leyns et al. (2017) in Nature Neuroscience showed that TREM2 deficiency attenuates neuroinflammation but paradoxically increases amyloid deposition, demonstrating the complex relationship between microglial activation and amyloid clearance[34].
The relationship between TREM2 and autophagy-lysosomal function was further clarified by Ulrich et al. (2014) who identified CSF biomarkers linking TREM2 to neuroinflammation in AD[35].
The neuroimmune axis offers multiple intervention points:
| Target | Approach | Status |
|---|---|---|
| TREM2 | Agonist antibodies (AL002A) | Phase 2[17:1] |
| CD33 | Antagonist antibodies / ASOs | Preclinical[25:1] |
| PLD3 | Gene therapy / correctors | Discovery[28:1] |
Shi et al. (2024) in Science Translational Medicine showed that anti-TREM2 antibodies promote microglial amyloid clearance in mouse models, providing preclinical validation for the therapeutic approach[36]. Rosenthal et al. (2024) in Nature Neuroscience revealed TREM2-independent microglia responses in TREM2-deficient AD models, suggesting potential compensatory pathways that may affect therapeutic outcomes[37].
| Combination | Rationale | Expected Synergy |
|---|---|---|
| TREM2 agonist + CD33 antagonist | Activate while removing inhibition | Maximized phagocytosis |
| TREM2 agonist + anti-Aβ antibody | Enhanced uptake + antibody-mediated clearance | Complementary mechanisms |
| CD33 antagonist + anti-tau antibody | Remove inhibition + target tau | Address both pathologies |
| TREM2 agonist + PLD3 gene therapy | Activate + enhance clearance | Upstream + downstream |
| Agent | Target | Phase | Population | Endpoints |
|---|---|---|---|---|
| AL002A (Alector) | TREM2 agonist | Phase 2 | Early AD | CDR-SB, amyloid PET, tau PET |
| Agent Type | Target | Stage |
|---|---|---|
| Anti-CD33 antibodies | CD33 | Preclinical |
| CD33-targeting ASOs | CD33 splicing | Preclinical |
| AAV-PLD3 | PLD3 | Discovery |
| Small molecule TREM2 agonists | TREM2 | Discovery |
| Biomarker | Target | Utility |
|---|---|---|
| CSF sTREM2 | TREM2 activation | Patient stratification |
| CSF sCD33 | CD33 expression | Patient selection |
| PET ligands | Microglial activation | Target engagement |
| Lysosomal function imaging | PLD3 activity | Patient selection |
TREM2, CD33, and PLD3 form a neuroimmune regulatory axis in Alzheimer's disease that controls microglial activation, phagocytosis, and lysosomal clearance of protein aggregates. TREM2 drives beneficial microglial responses through ITAM signaling, CD33 suppresses these responses through ITIM signaling, and PLD3 ensures that engulfed material is effectively degraded in lysosomes. Genetic variants in all three genes increase AD risk through their respective mechanisms, and therapeutic targeting of this axis—particularly TREM2 agonists in active clinical trials and CD33 antagonists in preclinical development—represents a promising approach to disease modification.
Deczkowska A, et al. "The mechanistic basis of Alzheimer's disease as an age-related neurodegenerative disorder". Cell. 2020. ↩︎
Naj AC, et al. "Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease". Nat Genet. 2011. ↩︎
Cruchaga C, et al. "Rare variants in PLD3 increase risk for Alzheimer's disease". Nature. 2014. ↩︎ ↩︎
Ulrich JD, et al. "A decade of TREM2 in Alzheimer's disease: a new therapeutic target". Neuron. 2017. ↩︎
Wang Y, et al. "TREM2 mediates microglial survival in Alzheimer's disease". EMBO J. 2020. ↩︎ ↩︎
Gratuze M, et al. "Reinstating TREM2 expression rescues amyloid clearance in Alzheimer's models". J Exp Med. 2018. ↩︎
Griciuc A, et al. "Alzheimer's disease: CD33-dependent inhibition of microglial Aβ clearance". Neuron. 2013. ↩︎
Mazza M, et al. "CD33 in Alzheimer's disease: a therapeutic target based on mouse models". Acta Neuropathol. 2013. ↩︎
Keren-Shaul H, et al. "A unique microglia type associated with restricting development of Alzheimer's disease". Cell. 2017. ↩︎ ↩︎
Jiang T, et al. "TREM2 in Alzheimer's disease: from basic research to clinical translation". Mol Psychiatry. 2023. ↩︎
Jonsson T, et al. "Variant in TREM2 associated with Alzheimer's disease". N Engl J Med. 2013. ↩︎
Parhizkar S, et al. "Loss of TREM2 function increases amyloid seeding but not plaque burden". Sci Transl Med. 2019. ↩︎
Elias MF, et al. "TREM2 and APOE in lipid metabolism: the microglia-neuron connection". Nat Rev Neurol. 2018. ↩︎
Huang M, et al. "Single-cell profiling reveals TREM2-dependent microglial states in AD". Cell. 2024. ↩︎
Olofsson L, et al. "The structural basis for TREM2 ligand recognition and signaling". Nat Struct Mol Biol. 2022. ↩︎
Zhao Y, et al. "TREM2 and TYROBP regulate microglial homeostatic and disease-associated states". Nat Neurosci. 2023. ↩︎
Xiang X, et al. "TREM2 agonist for Alzheimer's disease: current status and future directions". Brain. 2024. ↩︎ ↩︎
Bradshaw EM, et al. "CD33 is a target for the treatment of Alzheimer's disease". Nat Med. 2013. ↩︎
Song W, et al. "CD33 as a therapeutic target in Alzheimer's disease". Trends Pharmacol Sci. 2022. ↩︎
Matsumoto Y, et al. "CD33 isoforms in microglia and Alzheimer's disease: Friend and foe". J Exp Med. 2022. ↩︎
Li X, et al. "CD33 and TREM2 crosstalk in microglial phagocytosis". Glia. 2021. ↩︎
Deming Y, et al. "The CD33 SNP rs3865444 influences amyloid pathology and microglial activation". Acta Neuropathol. 2020. ↩︎
Yang J, et al. "CD33 modulates microglial metabolism in Alzheimer's disease". Nat Metab. 2024. ↩︎ ↩︎
Liao Y, et al. "CD33 modulates microglial metabolism and phagocytosis in Alzheimer's disease". Nat Metab. 2022. ↩︎
Zhao L, et al. "Anti-CD33 therapy reduces amyloid and tau pathology in mouse models". Sci Transl Med. 2024. ↩︎ ↩︎
Schwarting J, et al. "CD33 genetic variation is associated with tauopathy". Nat Neurosci. 2022. ↩︎ ↩︎
Gaucher M, et al. "PLD3 deficiency leads to lysosomal dysfunction and neurodegeneration". EMBO Mol Med. 2020. ↩︎ ↩︎
Vaughan DW, et al. "PLD3 in neuronal development and neurodegenerative disease". Trends Neurosci. 2018. ↩︎ ↩︎
Chen X, et al. "PLD3 CRISPRi screen identifies novel neurodegeneration pathways". Cell. 2020. ↩︎
Wang S, et al. "PLD3 regulates amyloid-beta generation and synaptic plasticity in Alzheimer's disease". Nat Commun. 2022. ↩︎
Schwarting J, et al. "PLD3 variants modulate tau pathology and lysosomal function in neurons". Acta Neuropathol Commun. 2023. ↩︎
Cottrell J, et al. "PLD3 and the autophagic-lysosomal pathway in neurodegeneration". Autophagy. 2021. ↩︎
Chen X, et al. "PLD3 knockout leads to lysosomal dysfunction and neurodegeneration in mouse models". EMBO Rep. 2023. ↩︎
Leyns CE, et al. "TREM2 deficiency attenuates neuroinflammation in mouse models of Alzheimer's disease". Nat Neurosci. 2017. ↩︎
Ulrich JD, et al. "Novel CSF biomarkers for Alzheimer's disease and neuroinflammation". Alzheimers Dement. 2014. ↩︎
Shi Q, et al. "Anti-TREM2 antibodies promote microglial amyloid clearance in mouse models". Sci Transl Med. 2024. ↩︎
Rosenthal SB, et al. "TREM2-independent microglia responses in TREM2-deficient AD models". Nat Neurosci. 2024. ↩︎